About PolpharmaWe are the largest Polish manufacturer of pharmaceuticals and a leader of the Polish pharmaceutical market. We actively operate in the markets of Central and Eastern Europe, the Caucasus and Central Asia.
Sustainable development/ESG“We help people live healthy lives in a healthy world”. This is our mission, which reflects Polpharma’s priorities. We provide patients with high-quality, effective, safe and accessible products while operating responsibly in the society, the environment and with respect to key stakeholders.
CareerPolpharma's development is possible only thanks to the commitment of our employees as well as the involvement of students and graduates in various business areas.
Other PRICE INQUIRY No. SEMA/69/PR123617/2025 – being conducted as a market assessment study 10 September 2025In connection with the implementation of the project titled “Development and advancement of an innovative solution – a generic drug from the group of GLP-1… read more
Other PRICE INQUIRY No. SEMA 70/PR113719/2025 – being conducted as a market assessment study 08 September 2025In connection with the implementation of the project entitled “Development of a universal fastresponse platform, based on RNA technology, ensuring the national drug and epidemiological… read more
Other PRICE INQUIRY No. SEMA 66/PR113719/2025 – being conducted as a market assessment study 06 August 2025In connection with the implementation of the project entitled “Development of a universal fastresponse platform, based on RNA technology, ensuring the national drug and epidemiological… read more
Other PRICE INQUIRY No. NUSI/124/PR113373/2025 – being conducted as a market assessment study 18 June 2025In connection with the implementation of the project titled “Development of a universal fast-response platform, based on RNA technology, ensuring the national drug and epidemiological… read more
Company News Other Polpharma Group Supports Urgent EU Action to Safeguard Access to Medicines and Strengthen European Pharmaceutical Sovereignty04 June 2025The letter, signed by CEOs and senior executives from across the European off-patent medicines sector, focuses on the need to: Accelerate the adoption of the… read more
